GLP-1 obesity drugs linked to fewer alcohol hospitalizations
A multi-trial analysis of about 40,700 adults found GLP-1 receptor agonists such as semaglutide and tirzepatide are associated with substantially lower alcohol-related hospital admissions across diabetics, obesity, and alcohol-use disorder groups, with reductions ranging from roughly 26% to 65% depending on the comparison. Experts say the findings hint at a potential role for these weight‑loss and diabetes drugs in treating alcohol-use disorders, though more research is needed to confirm causality and guide use.
